TVTX · Travere Therapeutics, Inc.
Market Cap
$6.19B
Shares
94.26M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$490.73M
+110.5%
FY2025
Net Income
-$25.55M
+92.1%
FY2025
Gross Margin
97.89%
+1.2pp
FY2025
Operating Margin
-12.8%
+126.1pp
FY2025
Diluted EPS
-$0.29
+92.9%
FY2025
Operating Cash Flow
$37.78M
+115.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $591.33M | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M | $198.32M | $175.34M | $164.25M | $154.94M | $133.59M | — | — | — | — | $0 | |
| — | — | — | — | — | — | — | — | $5.5M | $3.23M | $3.98M | — | — | — | — | — | |
| $8.26M | $10.34M | $7.74M | $11.45M | $4.42M | $3.82M | $6.13M | $5.23M | $5.53M | $3.61M | $4.55M | $2.19M | $571K | $0 | — | — | |
| $583.07M | $480.39M | $225.43M | $133.79M | $105.04M | $128.02M | $192.2M | $170.1M | $158.72M | $151.33M | $129.04M | — | — | — | — | — | |
| — | 97.89% | 96.68% | 92.12% | 95.96% | 97.1% | 96.91% | 97.01% | 96.63% | 97.67% | 96.59% | — | — | — | — | — | |
| $227.14M | $206.01M | $217.5M | $244.99M | $7.5M | $201.16M | $131.77M | $140.96M | $123.76M | $78.17M | $70.82M | $50.43M | $47.8M | $7.08M | $662.5K | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $12.83K | |
| $390.57M | $337.2M | $264.12M | $265.54M | $197.52M | $126.28M | $135.8M | $128.95M | $103.65M | $101.33M | $91.94M | $79.54M | $59.65M | $17.69M | $29.59M | — | |
| $61.81M | $59.21M | $41.74M | $36.28M | $18.6M | $11.05M | $22.44M | $19.71M | $18.03M | $17.33M | $15.99M | $13.23M | $5.28M | $324K | — | — | |
| $63.37M | $60.74M | $43.56M | $38.53M | $20.72M | $12.75M | $24.58M | $20.41M | $18.67M | $17.8M | $16.14M | $13.39M | $5.4M | $216K | $124.89K | — | |
| — | $0 | $2.44M | $11.39M | $0 | $0 | $0 | $0 | -$242K | $3.61M | $893K | $0 | — | — | — | — | |
| — | — | — | — | — | — | — | — | $244.29M | $208.73M | $191.81M | $150.64M | $108.01M | $24.77M | $30.26M | — | |
| $631.79M | $553.55M | $557M | $533.38M | $429.27M | $331.26M | $374.48M | $312.7M | $244.29M | $208.73M | — | — | — | — | — | $14.83K | |
| -$40.46M | -$62.82M | -$323.83M | -$388.14M | -$319.81M | -$199.43M | -$176.16M | -$137.36M | -$80.04M | -$53.79M | -$58.21M | -$50.75M | -$79.81M | -$24.77M | -$30.26M | — | |
| — | -12.8% | -138.88% | -267.24% | -292.17% | -151.27% | -88.83% | -78.34% | -48.73% | -34.72% | -43.58% | — | — | — | — | — | |
| $22.91M | -$2.08M | -$280.27M | -$349.61M | -$299.09M | -$186.68M | -$151.58M | -$116.95M | -$61.37M | -$35.99M | -$42.08M | -$37.36M | -$74.41M | -$24.56M | -$30.13M | — | |
| $9.48M | $10.75M | $11.18M | $11.3M | $11M | $19.7M | $19.1M | $18.8M | $9.81M | $4.42M | $4.73M | $7.7M | $7.4M | $0 | $84.09K | — | |
| $11.58M | $12.72M | $17.82M | $21.77M | $6.28M | $1.99M | $5M | $10.06M | $5.5M | $3.23M | — | — | — | — | — | — | |
| -$26.61M | $13.55M | $3.32M | $12.03M | -$11.34M | -$17.46M | -$12.63M | -$9.09M | -$21.83M | -$4.57M | $632K | $156.22M | -$33.59M | -$9.78M | -$86.84K | — | |
| -$67.07M | -$49.27M | -$320.51M | -$376.11M | -$331.16M | -$216.88M | -$188.79M | -$146.45M | -$101.87M | -$58.36M | -$57.58M | $105.47M | -$113.4M | -$34.55M | -$30.34M | — | |
| $605K | $988K | $120K | $223K | $313K | $409K | -$19.36M | -$21K | $811K | $1.37M | -$9.68M | -$11.77M | -$2.46M | $76K | — | — | |
| -$43.46M | -$25.55M | -$321.55M | -$111.4M | -$278.48M | -$180.09M | -$169.43M | -$146.43M | -$102.68M | -$59.73M | -$47.9M | $117.24M | -$110.94M | -$34.63M | -$30.34M | -$14.83K | |
| — | -5.21% | -137.9% | -76.7% | -254.41% | -136.6% | -85.43% | -83.51% | -62.51% | -38.55% | -35.86% | — | — | — | — | — | |
| -$43.46M | -$25.55M | -$321.55M | -$111.4M | -$278.48M | -$180.09M | -$169.43M | -$146.43M | — | — | — | — | — | — | — | — | |
| -$43.77M | -$26.66M | -$320.17M | -$109.95M | -$280.83M | -$179.75M | -$171.06M | -$144.17M | -$103.19M | -$60.26M | -$47.71M | $112.27M | -$106.54M | -$34.74M | -$30.34M | — | |
| USD/shares | -$0.45 | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.49 | -$4.43 | -$2.44 | — | — |
| USD/shares | -$0.45 | -$0.29 | -$4.08 | -$1.50 | -$4.37 | -$3.01 | -$3.56 | -$3.46 | -$2.54 | -$1.54 | -$1.29 | $3.17 | -$4.43 | -$2.44 | — | — |
| shares | — | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 37M | 33.56M | 25.06M | 14.21M | 3.66M | 106.68K |
| shares | — | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 38.29M | 37.58M | 25.06M | 14.21M | 3.66M | 106.68K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2016: $3.22M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.55×
EV/EBIT
—
Peer median 26.12×
P/E (TTM)
—
Peer median 19.68×
Peer medians compare against the 178 similar-size Biotechnology companies (of 524 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $490,728,000 | $233,175,000 | $145,238,000 | $109,460,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $410,460,000 | $226,707,000 | — | $97,970,000 | $115,122,000 | $198,321,000 | $175,338,000 | — |
| FILSPARI | $322,005,000 | $132,222,000 | $29,208,000 | $0 | $0 | — | — | — |
| Tiopronin Products | $88,455,000 | $94,485,000 | $98,329,000 | $97,970,000 | $115,122,000 | $108,883,000 | — | — |
| License | $80,268,000 | $6,468,000 | — | $11,490,000 | $16,714,000 | $0 | $0 | — |
| Bile Acid Products | — | — | — | — | $95,654,000 | $89,438,000 | $79,700,000 | $75,070,000 |
| Thiola License | — | — | — | — | — | — | $95,638,000 | — |
| Tiopronin Products | — | — | — | — | $115,122,000 | $108,883,000 | $95,638,000 | $89,176,000 |
| Active Pharmaceutical Ingredient | — | — | $3,300,000 | — | — | — | — | — |
| Bile Acid Products | — | — | — | $102,558,000 | $95,654,000 | $89,438,000 | — | — |
| Clinical Development Activity | — | — | $14,400,000 | — | — | — | — | — |
Key facts
CIK
1438533
CUSIP
89422G107
13F (30d)
278 filings
273 filers
Visit website
Investor relations